(English) Cross-border pharma deal calls on multiple LatAm firms
Canadian publicly owned specialty pharmaceuticals company Knight Therapeutics has hired Davies Ward Phillips & Vineberg in Montréal, Pinheiro Neto Advogados in São Paulo, Ferrere (Uruguay), Brigard Urrutia in Bogotá and Beccar Varela in Buenos Aires to buy a majority stake in Uruguayan biopharmaceutical group Biotoscana, in a deal valued at 1.1 billion Brazilian reais (US$273 million).
Montevideo-headquartered Biotoscana hired Lobo de Rizzo Advogados in São Paulo and Posadas, Posadas & Vecino in Montevideo. The company is listed on the Brazilian stock exchange.
Biotoscana’s majority shareholders, Essex Woodlands and Advent International, were the sellers in the deal and relied on in-house counsel and Estudio Garrido Abogados in Buenos Aires. The transaction was signed on 18 October.
It is thought that Arendt & Medernach in Luxembourg City also advised Knight, but the firm did not confirm its participation prior to publishing. Bonn Steichen & Partners in Luxembourg City is also thought to be involved as representatives of Biotoscana, but neither confirmed their role.
Knight obtained a 51% majority stake valued at 595 million reais (US$149 million) from Advent International and Essex Woodlands. It will make a mandatory follow-on tender offer worth 568 million reais (US$142 million) to buy the remaining 49% from minority shareholders.
If shareholders accept the tender offer, the deal will reach a total of 1.1 billion reais (US$273 million), with the combined enterprise valued at a total of 1.3 billion reais (US$323 million).
Biotoscana has operations across 10 different countries within the region, including Brazil, Mexico, Argentina and Chile. The company specialises in providing innovative biopharmaceutical services.
Counsel to Knight Therapeutics
Davies Ward Phillips & Vineberg LLP
Partners Hillel Rosen and Brian Kujavsky and associate Shayna Goldman in Montréal
Pinheiro Neto Advogados
Partner Guilherme Sampaio Monteiro and associates Milena Casado de Oliveira and Taisa Sani in São Paulo
Partner Martin Cerruti and associates Cristina Vignone, Alejandro Alterwain, Manuel Graña, Carolina Piacenza, Bruno Bertolotti, María Maiorano, Diego Durán, Alberto Baroffio, Alejandra Añon, Martín Pesce, Cecilia Alberti, Joaquín Garino in Montevideo
Partners María Shakespear, Roberto Crouzel and Horacio E. Beccar Varela, and associates Luciana Liefeldt, Ana Andres, Florencia Cariella, Tomas Peña, Angeles Murgier, Elias Colabelli and Agustín Waisman in Buenos Aires
Partner Carlos Urrutia and associates Tomás Holguín and Sergio Andrés Velandia Cetina in Bogotá
Counsel to Grupo Biotoscana
In-house counsel – María Eugenia Cabezas
Lobo de Rizzo Advogados
Partners Rodrigo Millar de Castro Guerra and Paula Magalhães, and associates Julia Visconti, Gabriel Arruda Chueke, Jéssica Pfeifer Dalla Picola in São Paulo
Posadas, Posadas & Vecino
Partners Diego Gamarra, Fernando de Posadas and Diego Cuenca and associate Cecilia Demarco in Montevideo
Counsel to Advent International and Essex Woodlands
Estudio Garrido Abogados
Partners Lucas Granillo Ocampo and Raul Granillo Ocampo, and associates Gisela Marina Montensanto a Regina Gaggiotti in Buenos Aires
This article was updated on 13/11/19 to include Brigard Urrutia’s advice to Knight Therapeutics.
Source: Latin Lawyer
ver todas as publicacoes